AR100426A1 - ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3 - Google Patents
ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3Info
- Publication number
- AR100426A1 AR100426A1 ARP150101480A ARP150101480A AR100426A1 AR 100426 A1 AR100426 A1 AR 100426A1 AR P150101480 A ARP150101480 A AR P150101480A AR P150101480 A ARP150101480 A AR P150101480A AR 100426 A1 AR100426 A1 AR 100426A1
- Authority
- AR
- Argentina
- Prior art keywords
- her3
- amino acid
- acid sequence
- chain variable
- variable domain
- Prior art date
Links
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title abstract 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 102000057750 human ERBB3 Human genes 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La solicitud se refiere a anticuerpos anti-HER3 (factor de crecimiento epidérmico 3) específicos que se unen a la horquilla b de HER3, a su preparación y su uso como medicamento. Reivindicación 2: Un anticuerpo aislado que se une a HER3 humana, en el que el anticuerpo comprende: a) un dominio variable de cadena pesada VH con la secuencia de aminoácidos de SEC ID Nº 33; y b) un dominio variable de cadena ligera VL con la secuencia de aminoácidos de SEC ID Nº 41, un dominio variable de cadena ligera con la secuencia de aminoácidos de SEC ID Nº 39 o un dominio variable de cadena ligera con la secuencia de aminoácidos de SEC ID Nº 42.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14168335 | 2014-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100426A1 true AR100426A1 (es) | 2016-10-05 |
Family
ID=50729374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101480A AR100426A1 (es) | 2014-05-14 | 2015-05-13 | ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9783611B2 (es) |
| EP (1) | EP3143048B1 (es) |
| JP (1) | JP6433511B2 (es) |
| KR (1) | KR20160144465A (es) |
| CN (1) | CN106459207B (es) |
| AR (1) | AR100426A1 (es) |
| BR (1) | BR112016024457A2 (es) |
| CA (1) | CA2944895A1 (es) |
| MX (1) | MX2016014416A (es) |
| RU (1) | RU2016148682A (es) |
| TW (1) | TW201605902A (es) |
| WO (1) | WO2015173250A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6302476B2 (ja) | 2012-11-08 | 2018-03-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ３のベータヘアピンに結合するｈｅｒ３抗原結合タンパク質 |
| MX2015005756A (es) | 2012-11-08 | 2015-09-16 | Hoffmann La Roche | Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4. |
| EP3143048B1 (en) | 2014-05-14 | 2019-08-28 | F. Hoffmann-La Roche AG | Anti-her3 antibodies binding to the beta-hairpin of her3 |
| CN106255705B (zh) | 2014-05-14 | 2021-01-08 | 豪夫迈·罗氏有限公司 | 结合HER3β-发夹和HER2域II的HER3/HER2双特异性抗体 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| BR112021005246A2 (pt) * | 2018-09-20 | 2021-06-15 | Daiichi Sankyo Company, Limited | agente terapêutico, e, método de tratamento para câncer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| IL126303A (en) | 1996-03-27 | 2002-05-23 | Genentech Inc | ErbB3 ANTIBODIES |
| US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
| ES2391623T3 (es) | 2001-06-22 | 2012-11-28 | F. Hoffmann-La Roche Ag | Complejo soluble que contiene una glicoproteína de superficie retroviral |
| WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| JP2009532393A (ja) | 2006-04-07 | 2009-09-10 | コペンハーゲン ユニバーシティ | ＥｒｂＢ受容体由来ペプチド断片 |
| CA2655205A1 (en) | 2006-06-12 | 2007-12-21 | Receptor Biologix Inc. | Pan-cell surface receptor- specific therapeutics |
| ES2631727T3 (es) * | 2007-02-16 | 2017-09-04 | Merrimack Pharmaceuticals, Inc. | Anticuerpos contra el ErbB3 y usos de los mismos |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| CN102822201B (zh) | 2009-12-22 | 2014-09-24 | 罗切格利卡特公司 | 抗her3抗体及其用途 |
| AU2011254557B2 (en) * | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| BR112013004012B1 (pt) * | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| CN104105709A (zh) * | 2011-12-05 | 2014-10-15 | 诺华股份有限公司 | 抗her3的结构域ii的表皮生长因子受体3(her3)抗体 |
| WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| MX2015005756A (es) * | 2012-11-08 | 2015-09-16 | Hoffmann La Roche | Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4. |
| JP6302476B2 (ja) * | 2012-11-08 | 2018-03-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ３のベータヘアピンに結合するｈｅｒ３抗原結合タンパク質 |
| EP3143048B1 (en) | 2014-05-14 | 2019-08-28 | F. Hoffmann-La Roche AG | Anti-her3 antibodies binding to the beta-hairpin of her3 |
-
2015
- 2015-05-12 EP EP15721719.1A patent/EP3143048B1/en active Active
- 2015-05-12 BR BR112016024457A patent/BR112016024457A2/pt not_active Application Discontinuation
- 2015-05-12 CA CA2944895A patent/CA2944895A1/en not_active Abandoned
- 2015-05-12 WO PCT/EP2015/060492 patent/WO2015173250A1/en not_active Ceased
- 2015-05-12 US US14/710,194 patent/US9783611B2/en not_active Expired - Fee Related
- 2015-05-12 JP JP2016567203A patent/JP6433511B2/ja not_active Expired - Fee Related
- 2015-05-12 RU RU2016148682A patent/RU2016148682A/ru not_active Application Discontinuation
- 2015-05-12 CN CN201580022781.7A patent/CN106459207B/zh not_active Expired - Fee Related
- 2015-05-12 MX MX2016014416A patent/MX2016014416A/es unknown
- 2015-05-12 KR KR1020167031609A patent/KR20160144465A/ko not_active Ceased
- 2015-05-13 AR ARP150101480A patent/AR100426A1/es unknown
- 2015-05-13 TW TW104115311A patent/TW201605902A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016148682A (ru) | 2018-06-19 |
| BR112016024457A2 (pt) | 2018-01-23 |
| CA2944895A1 (en) | 2015-11-19 |
| EP3143048A1 (en) | 2017-03-22 |
| MX2016014416A (es) | 2017-02-23 |
| CN106459207B (zh) | 2020-07-10 |
| JP6433511B2 (ja) | 2018-12-05 |
| JP2017521050A (ja) | 2017-08-03 |
| EP3143048B1 (en) | 2019-08-28 |
| KR20160144465A (ko) | 2016-12-16 |
| US9783611B2 (en) | 2017-10-10 |
| TW201605902A (zh) | 2016-02-16 |
| US20160002338A1 (en) | 2016-01-07 |
| CN106459207A (zh) | 2017-02-22 |
| WO2015173250A1 (en) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132864A2 (es) | UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO | |
| PE20130560A1 (es) | Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2 | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| AR100426A1 (es) | ANTICUERPOS ANTI-HER3 QUE SE UNEN A LA HORQUILLA b DE HER3 | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| CL2016001723A1 (es) | Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos. | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
| MX2022006461A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
| BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| MX2021010471A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| MX374811B (es) | Anticuerpos anti-tau y métodos de uso. | |
| ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
| BR112017013111A2 (pt) | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo | |
| EA201500503A1 (ru) | Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4 | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| EA201890082A1 (ru) | Эпитоп антитела | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| EA201500502A1 (ru) | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |